Literature DB >> 9434260

Chronotoxicity of methotrexate in mice and its relation to circadian rhythm of DNA synthesis and pharmacokinetics.

S Ohdo1, K Inoue, E Yukawa, S Higuchi, S Nakano, N Ogawa.   

Abstract

The mechanisms underlying the circadian rhythm of methotrexate (MTX)-induced toxicity (body weight loss and leukopenia) were investigated from the viewpoints of the sensitivity of living organisms to the drug and the pharmacokinetics of the drug. ICR male mice were housed in a standardized light-dark cycle (lights on at 0700, off at 1900) with food and water ad libitum. The body weight loss after an intraperitoneal injection of MTX (400 mg/kg) was more serious in the late dark period and the early light period and milder in the late light period and the early dark period. The MTX-induced leukopenia was more serious in the late dark period and the light period and milder in the early dark period. Lower toxicity was observed when DNA synthesis, dihydrofolate reductase (DHFR) activity in bone marrow cells and folate level in plasma decreased, and higher toxicity was observed when they increased. There was a significant circadian rhythm in plasma MTX concentration, with a higher level in the light period and a lower level in the dark period. The circadian rhythm of plasma MTX concentration was associated with that of MTX-induced toxicity. The present study suggests that the circadian rhythm of MTX-induced toxicity is caused by that of the sensitivity of living organisms to the drug and the pharmacokinetics of the drug.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9434260     DOI: 10.1254/jjp.75.283

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  8 in total

1.  Effect of dosing schedule on pharmacokinetics of alpha interferon and anti-alpha interferon neutralizing antibody in mice.

Authors:  D S Wang; S Ohdo; S Koyanagi; H Takane; H Aramaki; E Yukawa; S Higuchi
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 2.  Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy.

Authors:  Brahma N Singh; Bimal K Malhotra
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  Effects of chemotherapeutic agents 5-fluorouracil and methotrexate alone and combined in a mouse model of learning and memory.

Authors:  John J Foley; Robert B Raffa; Ellen A Walker
Journal:  Psychopharmacology (Berl)       Date:  2008-05-08       Impact factor: 4.530

4.  The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy.

Authors:  Youqiong Ye; Yu Xiang; Fatma Muge Ozguc; Yoonjin Kim; Chun-Jie Liu; Peter K Park; Qingsong Hu; Lixia Diao; Yanyan Lou; Chunru Lin; An-Yuan Guo; Bingying Zhou; Li Wang; Zheng Chen; Joseph S Takahashi; Gordon B Mills; Seung-Hee Yoo; Leng Han
Journal:  Cell Syst       Date:  2018-03-07       Impact factor: 10.304

5.  Candidate SNP Markers of Chronopathologies Are Predicted by a Significant Change in the Affinity of TATA-Binding Protein for Human Gene Promoters.

Authors:  Petr Ponomarenko; Dmitry Rasskazov; Valentin Suslov; Ekaterina Sharypova; Ludmila Savinkova; Olga Podkolodnaya; Nikolay L Podkolodny; Natalya N Tverdokhleb; Irina Chadaeva; Mikhail Ponomarenko; Nikolay Kolchanov
Journal:  Biomed Res Int       Date:  2016-08-22       Impact factor: 3.411

6.  The Circadian Clock Gene Bmal1 Controls Intestinal Exporter MRP2 and Drug Disposition.

Authors:  Fangjun Yu; Tianpeng Zhang; Cui Zhou; Haiman Xu; Lianxia Guo; Min Chen; Baojian Wu
Journal:  Theranostics       Date:  2019-04-13       Impact factor: 11.556

7.  Chronopharmacology and mechanism of antitumor effect of erlotinib in Lewis tumor-bearing mice.

Authors:  Peipei Wang; Fengmei An; Xingjun Zhuang; Jiao Liu; Liyan Zhao; Bin Zhang; Liang Liu; Pingping Lin; Mingchun Li
Journal:  PLoS One       Date:  2014-07-07       Impact factor: 3.240

8.  Diurnal expression of MRP4 in bone marrow cells underlies the dosing-time dependent changes in the oxaliplatin-induced myelotoxicity.

Authors:  Mizuki Kato; Yuya Tsurudome; Takumi Kanemitsu; Sai Yasukochi; Yuki Kanado; Takashi Ogino; Naoya Matsunaga; Satoru Koyanagi; Shigehiro Ohdo
Journal:  Sci Rep       Date:  2020-08-10       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.